Navigation Links
Abbott Announces Approval in China for Next-Generation XIENCE V(R) Drug Eluting Stent
Date:9/14/2009

ABBOTT PARK, Ill., Sept. 14 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) announced today that the Chinese State Food and Drug Administration (SFDA) has approved its XIENCE V(R) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease (CAD) - the leading cause of death in China. XIENCE V is the only drug eluting stent to have demonstrated superiority over the TAXUS(R) Paclitaxel-Eluting Coronary Stent System (TAXUS) in the primary endpoints of two randomized, pivotal (phase III) clinical trials. The company plans a fourth-quarter launch for XIENCE V in China, which is the second-largest drug eluting stent market in the Asia-Pacific region after Japan. With approval in China, XIENCE V is now available in every Asia-Pacific market except Japan, where approval is anticipated at the end of this year.

"Since it first became commercially available in 2006, XIENCE V has become the market-leading drug eluting stent around the world due to its excellent outcomes and outstanding deliverability," said Robert Hance, senior vice president, vascular, Abbott. "As the incidence of heart disease and the number of annual stent procedures continue to increase in China, it is critical for physicians and patients to have access to one of the most advanced drug eluting stent technologies. We look forward to making XIENCE V available in China."

According to the China Chronic Heart Disease 2006 Annual Report, nearly 50 percent of all deaths annually in China are due to CAD, and the prevalence of coronary artery disease has steadily increased each year. Approximately 150,000 patients annually undergo a stent procedure for the treatment of CAD, and the number of procedures is growing by more than 20 percent each year in China.

"Heart disease is a
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Abbott to Acquire Evalve, Inc., a Leader in Minimally Invasive Cardiac Valve Repair Technology
2. Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial
3. Abbott HIV Test Demonstrates Earlier Disease Detection
4. Centocor Ortho Biotech Inc. Awarded $1.67 Billion Patent Jury Verdict from Abbott Laboratories
5. Abbott & BioGenex Extend the Technology Co-development and Distribution Agreement for Marketing the Xmatrx(R) Advanced Staining Platform for the Automation of FISH, IHC and ISH Molecular Diagnostic Assays
6. Abbott Named One of the Top 10 Companies for Scientists
7. HUYA Bioscience Announces Strategic Alliance With Abbott on Drug and Biomarker Development Candidates From China
8. Abbott to Present at Barclays Global Healthcare Conference
9. Abbott Employee Giving Sets New Records for Employee Participation and Total Donations
10. Abbott Announces 11 Percent Increase in Quarterly Dividend
11. Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Palm Beach County, Florida (PRWEB) August 27, 2014 ... & Company Inc. (SCI) is announcing the creation ... board’s priority is to take the SCI’s philosophy ... insuring the company’s research and development actions are ... interpretations. , This new Scientific Advisory Board provides ...
(Date:8/27/2014)... After the boom of the energy ... beverage craze is going to be the stress relief ... use Stress Relief energy pattern which can be applied ... a beverage, including minerals, herbs and liquids. Stress Relief ... power into rapid recovery and helping to adapt more ...
(Date:8/27/2014)... Remcom announces an update to XFdtd® ... the biomedical industry. The central biomedical addition in ... to the Bio-Pro version of the software. XFdtd ... calculate the biological effects of electromagnetic fields. In ... versions to expand engineers’ post-processing options. , The Biological ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Budding ... Cleveland's University School participated in the ... Western Reserve University’s School of Medicine . ... with an unparalleled professional experience in the sciences ... of Medicine faculty and students for both academic ...
Breaking Biology Technology:New Sancilio & Company, Inc. Scientific Board 2New Sancilio & Company, Inc. Scientific Board 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 4Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 2Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 3Students at Cleveland's University School Conduct Biomedical Research at Case Western Reserve University’s School of Medicine 2
... ... ... , ... OXFORD, England and LANGHORNE, Pennsylvania, ...
... ... ... , ... ...
... , ... ... ... ...
Cached Biology Technology:EUSA Pharma Completes Establishment of Commercial Infrastructure With Appointment of President for Europe and International Region 2EUSA Pharma Completes Establishment of Commercial Infrastructure With Appointment of President for Europe and International Region 3EUSA Pharma Completes Establishment of Commercial Infrastructure With Appointment of President for Europe and International Region 4Ten Million Flex-Fuel Vehicles in Brazil a Milestone that Deserves Global Dissemination by Automakers 2Ten Million Flex-Fuel Vehicles in Brazil a Milestone that Deserves Global Dissemination by Automakers 3Ten Million Flex-Fuel Vehicles in Brazil a Milestone that Deserves Global Dissemination by Automakers 4Ten Million Flex-Fuel Vehicles in Brazil a Milestone that Deserves Global Dissemination by Automakers 5Ten Million Flex-Fuel Vehicles in Brazil a Milestone that Deserves Global Dissemination by Automakers 6Ten Million Flex-Fuel Vehicles in Brazil a Milestone that Deserves Global Dissemination by Automakers 7MedShape Solutions, Inc. Announces Commercialization of SBIR Funded Technology: Receives Purchasing Preference in Federally Funded Hospitals and Health Care Facilities 2MedShape Solutions, Inc. Announces Commercialization of SBIR Funded Technology: Receives Purchasing Preference in Federally Funded Hospitals and Health Care Facilities 3MedShape Solutions, Inc. Announces Commercialization of SBIR Funded Technology: Receives Purchasing Preference in Federally Funded Hospitals and Health Care Facilities 4
(Date:8/27/2014)... 27, 2014  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today ... public offering of units of common stock and warrants ... proceeds of $20 million, prior to deducting underwriting discounts ... The shares and warrants are immediately separable and will ... in the offering consists of 2,000 shares of common ...
(Date:8/27/2014)... of North America,s megafauna mastodons, short-faced bears, giant ... disappeared close to 13,000 years ago at the ... massive extinction has long been debated by scientists who, ... A group of scientists, including UC Santa Barbara,s James ... posited that a comet collision with Earth played a ...
(Date:8/27/2014)... of the human genome was unveiled today in the ... comparison yet of how the genomes of the fruit ... appearing August 28 in in the journal Nature ... species, genomes is "read out," and how their DNA ... add billions of entries to a publicly available archive ...
Breaking Biology News(10 mins):WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3Nanodiamonds are forever 2Nanodiamonds are forever 3Encyclopedia of how genomes function gets much bigger 2Encyclopedia of how genomes function gets much bigger 3Encyclopedia of how genomes function gets much bigger 4
... arrhythmias are killers. They strike without ... about 10 percent of all deaths in the ... molecular mechanism associated with arrhythmias. Their findings, reported ... could lead to novel arrhythmia treatments., "The current ...
... expedition in 1965 to trap moths on Mount Kinabalu in ... groundwork for a study of the impacts of climate change. ... has repeated the survey 42 years later, and found that, ... over the intervening years to cope with changes in climate. ...
... and food research, is coordinating the international TXOTX ... fundamental aim of this project is to collate ... programs from the different regions in the world,s ... cooperation between countries, regional fisheries organisations and other ...
Cached Biology News:Studies point to novel target for treating arrhythmias 2Studies point to novel target for treating arrhythmias 3The global impact of climate change on biodiversity 2TXOTX, coordinated international project to contribute to sustainability of the marine resources 2
Anti-Chicken IgY, (IgG) F(ab')2 Fragment Specific....
Recognizes a full-length CLC-2 voltage-gated Cl- protein and not with other known proteins tested so far....
... Monoclonal Antibody, Unconjugated Applications: ... ICC: Use at an assay dependent dilution. WB: ... ug/ml, this concentration is determined using a whole ... kDa. Not tested in other applications. Optimal ...
Recognizes TWIK-2. Does not cross react with any other known proteins....
Biology Products: